Fusion Antibodies (LON:FAB) Shares Down 4.4% – Here’s Why

Fusion Antibodies plc (LON:FAB)’s stock price traded down 4.4% during mid-day trading on Thursday . The company traded as low as GBX 10.50 and last traded at GBX 10.75. Approximately 289,250 shares were traded during trading, a decline of 28% from the average daily volume of 403,048 shares. The stock had previously closed at GBX 11.25.

Fusion Antibodies Price Performance

The firm has a fifty day moving average of GBX 10.88 and a 200 day moving average of GBX 12.46. The company has a current ratio of 1.80, a quick ratio of 2.36 and a debt-to-equity ratio of 92.42. The company has a market capitalization of £13.46 million, a P/E ratio of -7.17 and a beta of 1.22.

About Fusion Antibodies

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.